Compare FTK & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTK | DSGN |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.1M | 579.9M |
| IPO Year | 1997 | 2021 |
| Metric | FTK | DSGN |
|---|---|---|
| Price | $16.84 | $10.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $20.00 | $15.25 |
| AVG Volume (30 Days) | ★ 280.8K | 247.6K |
| Earning Date | 03-11-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.06 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $136,092,000.00 | N/A |
| Revenue This Year | $11.40 | N/A |
| Revenue Next Year | $18.40 | N/A |
| P/E Ratio | $19.65 | ★ N/A |
| Revenue Growth | ★ 214.53 | N/A |
| 52 Week Low | $6.05 | $2.62 |
| 52 Week High | $20.41 | $11.23 |
| Indicator | FTK | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 49.12 |
| Support Level | $16.25 | $9.64 |
| Resistance Level | $17.12 | $11.14 |
| Average True Range (ATR) | 1.47 | 0.60 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 35.53 | 34.09 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.